MLYS
NASDAQ HealthcareMineralys Therapeutics, Inc. - Common Stock
Biotechnology
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
�� 市场数据
| 价格 | $30.58 |
|---|---|
| 成交量 | 1,013,502 |
| 市值 | 2.52B |
| 贝塔系数 | 0.690 |
| RSI（14日） | 78.8 超买 |
| 200日均线 | $30.32 |
| 50日均线 | $27.39 |
| 52周最高 | $47.65 |
| 52周最低 | $12.59 |
| Forward P/E | -16.71 |
| Price / Book | 3.86 |
🎯 投资策略评分
MLYS 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (69/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🚀 Moon Shot (24/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 MLYS in your text
粘贴任何文章、记录或帖子 — 工具将提取 MLYS 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.